Search

Your search keyword '"Cao, Longxing"' showing total 164 results
Start Over Author "Cao, Longxing"
164 results on '"Cao, Longxing"'

4. De novo design of luciferases using deep learning.

Author

Yeh, Andy Hsien-Wei, Norn, Christoffer, Kipnis, Yakov, Tischer, Doug, Pellock, Samuel J, Evans, Declan, Ma, Pengchen, Lee, Gyu Rie, Zhang, Jason Z, Anishchenko, Ivan, Coventry, Brian, Cao, Longxing, Dauparas, Justas, Halabiya, Samer, DeWitt, Michelle, Carter, Lauren, Houk, KN, and Baker, David

Subjects
Luciferases, Enzyme Stability, Catalytic Domain, Substrate Specificity, Oxidation-Reduction, Luminescence, Hot Temperature, Biocatalysis, Deep Learning, Luciferins, Biotechnology, Generic health relevance, General Science & Technology
Abstract

De novo enzyme design has sought to introduce active sites and substrate-binding pockets that are predicted to catalyse a reaction of interest into geometrically compatible native scaffolds1,2, but has been limited by a lack of suitable protein structures and the complexity of native protein sequence-structure relationships. Here we describe a deep-learning-based 'family-wide hallucination' approach that generates large numbers of idealized protein structures containing diverse pocket shapes and designed sequences that encode them. We use these scaffolds to design artificial luciferases that selectively catalyse the oxidative chemiluminescence of the synthetic luciferin substrates diphenylterazine3 and 2-deoxycoelenterazine. The designed active sites position an arginine guanidinium group adjacent to an anion that develops during the reaction in a binding pocket with high shape complementarity. For both luciferin substrates, we obtain designed luciferases with high selectivity; the most active of these is a small (13.9 kDa) and thermostable (with a melting temperature higher than 95 °C) enzyme that has a catalytic efficiency on diphenylterazine (kcat/Km = 106 M-1 s-1) comparable to that of native luciferases, but a much higher substrate specificity. The creation of highly active and specific biocatalysts from scratch with broad applications in biomedicine is a key milestone for computational enzyme design, and our approach should enable generation of a wide range of luciferases and other enzymes.

Published
2023

5. Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies

Author

Edman, Natasha I., Phal, Ashish, Redler, Rachel L., Schlichthaerle, Thomas, Srivatsan, Sanjay R., Ehnes, Devon Duron, Etemadi, Ali, An, Seong J., Favor, Andrew, Li, Zhe, Praetorius, Florian, Gordon, Max, Vincent, Thomas, Marchiano, Silvia, Blakely, Leslie, Lin, Chuwei, Yang, Wei, Coventry, Brian, Hicks, Derrick R., Cao, Longxing, Bethel, Neville, Heine, Piper, Murray, Analisa, Gerben, Stacey, Carter, Lauren, Miranda, Marcos, Negahdari, Babak, Lee, Sangwon, Trapnell, Cole, Zheng, Ying, Murry, Charles E., Schweppe, Devin K., Freedman, Benjamin S., Stewart, Lance, Ekiert, Damian C., Schlessinger, Joseph, Shendure, Jay, Bhabha, Gira, Ruohola-Baker, Hannele, and Baker, David

Published
2024
Full Text
View/download PDF

7. Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice

Author

Hunt, Andrew C, Case, James Brett, Park, Young-Jun, Cao, Longxing, Wu, Kejia, Walls, Alexandra C, Liu, Zhuoming, Bowen, John E, Yeh, Hsien-Wei, Saini, Shally, Helms, Louisa, Zhao, Yan Ting, Hsiang, Tien-Ying, Starr, Tyler N, Goreshnik, Inna, Kozodoy, Lisa, Carter, Lauren, Ravichandran, Rashmi, Green, Lydia B, Matochko, Wadim L, Thomson, Christy A, Vögeli, Bastian, Krüger, Antje, VanBlargan, Laura A, Chen, Rita E, Ying, Baoling, Bailey, Adam L, Kafai, Natasha M, Boyken, Scott E, Ljubetič, Ajasja, Edman, Natasha, Ueda, George, Chow, Cameron M, Johnson, Max, Addetia, Amin, Navarro, Mary Jane, Panpradist, Nuttada, Gale, Michael, Freedman, Benjamin S, Bloom, Jesse D, Ruohola-Baker, Hannele, Whelan, Sean PJ, Stewart, Lance, Diamond, Michael S, Veesler, David, Jewett, Michael C, and Baker, David

Subjects
Medical Biotechnology, Engineering, Biomedical and Clinical Sciences, Biomedical Engineering, Vaccine Related, Lung, Emerging Infectious Diseases, Biodefense, Pneumonia, Autoimmune Disease, Infectious Diseases, Pneumonia & Influenza, Prevention, Biotechnology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Animals, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Cryoelectron Microscopy, Humans, Mice, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.

Published
2022

11. De novo design of modular and tunable protein biosensors

Author

Quijano-Rubio, Alfredo, Yeh, Hsien-Wei, Park, Jooyoung, Lee, Hansol, Langan, Robert A, Boyken, Scott E, Lajoie, Marc J, Cao, Longxing, Chow, Cameron M, Miranda, Marcos C, Wi, Jimin, Hong, Hyo Jeong, Stewart, Lance, Oh, Byung-Ha, and Baker, David

Subjects
Analytical Chemistry, Biochemistry and Cell Biology, Chemical Sciences, Biological Sciences, Emerging Infectious Diseases, Bioengineering, Infectious Diseases, Generic health relevance, Good Health and Well Being, Antibodies, Viral, Biosensing Techniques, Botulinum Toxins, Coronavirus Nucleocapsid Proteins, Hepatitis B virus, Immunoglobulin G, Limit of Detection, Luminescence, Phosphoproteins, Proto-Oncogene Proteins c-bcl-2, Receptor, ErbB-2, SARS-CoV-2, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus, Troponin I, Viral Matrix Proteins, Receptor, erbB-2, General Science & Technology
Abstract

Naturally occurring protein switches have been repurposed for the development of biosensors and reporters for cellular and clinical applications1. However, the number of such switches is limited, and reengineering them is challenging. Here we show that a general class of protein-based biosensors can be created by inverting the flow of information through de novo designed protein switches in which the binding of a peptide key triggers biological outputs of interest2. The designed sensors are modular molecular devices with a closed dark state and an open luminescent state; analyte binding drives the switch from the closed to the open state. Because the sensor is based on the thermodynamic coupling of analyte binding to sensor activation, only one target binding domain is required, which simplifies sensor design and allows direct readout in solution. We create biosensors that can sensitively detect the anti-apoptosis protein BCL-2, the IgG1 Fc domain, the HER2 receptor, and Botulinum neurotoxin B, as well as biosensors for cardiac troponin I and an anti-hepatitis B virus antibody with the high sensitivity required to detect these molecules clinically. Given the need for diagnostic tools to track the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3, we used the approach to design sensors for the SARS-CoV-2 spike protein and antibodies against the membrane and nucleocapsid proteins. The former, which incorporates a de novo designed spike receptor binding domain (RBD) binder4, has a limit of detection of 15 pM and a luminescence signal 50-fold higher than the background level. The modularity and sensitivity of the platform should enable the rapid construction of sensors for a wide range of analytes, and highlights the power of de novo protein design to create multi-state protein systems with new and useful functions.

Published
2021

13. Design of protein-binding proteins from the target structure alone

Author

Cao, Longxing, Coventry, Brian, Goreshnik, Inna, Huang, Buwei, Sheffler, William, Park, Joon Sung, Jude, Kevin M., Marković, Iva, Kadam, Rameshwar U., Verschueren, Koen H. G., Verstraete, Kenneth, Walsh, Scott Thomas Russell, Bennett, Nathaniel, Phal, Ashish, Yang, Aerin, Kozodoy, Lisa, DeWitt, Michelle, Picton, Lora, Miller, Lauren, Strauch, Eva-Maria, DeBouver, Nicholas D., Pires, Allison, Bera, Asim K., Halabiya, Samer, Hammerson, Bradley, Yang, Wei, Bernard, Steffen, Stewart, Lance, Wilson, Ian A., Ruohola-Baker, Hannele, Schlessinger, Joseph, Lee, Sangwon, Savvides, Savvas N., Garcia, K. Christopher, and Baker, David

Published
2022
Full Text
View/download PDF

15. Structure of scavenger receptor SCARF1 and its interaction with lipoproteins

Author

Wang, Yuanyuan, primary, Xu, Fan, additional, Li, Guangyi, additional, Cheng, Chen, additional, Yu, Bowen, additional, Zhang, Ze, additional, Kong, Dandan, additional, Chen, Fabao, additional, Liu, Yali, additional, Fang, Zhen, additional, Cao, Longxing, additional, Yang, Yu, additional, Gu, Yijun, additional, and He, Yongning, additional

Published
2024
Full Text
View/download PDF

17. Structure of scavenger receptor SCARF1 and its interaction with lipoproteins

Author

Wang, Yuanyuan, primary, Xu, Fan, additional, Li, Guangyi, additional, Cheng, Chen, additional, Yu, Bowen, additional, Zhang, Ze, additional, Kong, Dandan, additional, Chen, Fabao, additional, Liu, Yali, additional, Fang, Zhen, additional, Cao, Longxing, additional, Yang, Yu, additional, Gu, Yijun, additional, and He, Yongning, additional

Published
2023
Full Text
View/download PDF

18. Designed Endocytosis-Triggering Proteins mediate Targeted Degradation and amplify signaling

Author

Huang, Buwei, primary, Abedi, Mohamad, additional, Ahn, Green, additional, Coventry, Brian, additional, Sappington, Isaac, additional, Wang, Rong, additional, Schlichthaerle, Thomas, additional, Zhang, Jason Z., additional, Wang, Yujia, additional, Goreshnik, Inna, additional, Chiu, Ching Wen, additional, Chazin-Gray, Adam, additional, Chan, Sidney, additional, Gerben, Stacey, additional, Murray, Analisa, additional, Wang, Shunzhi, additional, O'Neill, Jason, additional, Yeh, Ronald, additional, Misquith, Ayesha, additional, Wolf, Anitra, additional, Tomasovic, Luke M., additional, Piraner, Dan I, additional, Gonzalez, Maria J. Duran, additional, Bennett, Nathaniel R., additional, Venkatesh, Preetham, additional, Ahlrichs, Maggie, additional, Dobbins, Craig, additional, Yang, Wei, additional, Wang, Xinru, additional, Vafeados, Dionne, additional, Mout, Rubul, additional, Shivaei, Shirin, additional, Cao, Longxing, additional, Carter, Lauren, additional, Stewart, Lance, additional, Spangler, Jamie B., additional, Bernardes, Goncalo J.L., additional, Roybal, Kole T., additional, Greisen, Per Jr., additional, Li, Xiaochun, additional, Bertozzi, Carolyn, additional, and Baker, David, additional

Published
2023
Full Text
View/download PDF

19. Top-down design of protein architectures with reinforcement learning

Author

Lutz, Isaac D., primary, Wang, Shunzhi, additional, Norn, Christoffer, additional, Courbet, Alexis, additional, Borst, Andrew J., additional, Zhao, Yan Ting, additional, Dosey, Annie, additional, Cao, Longxing, additional, Xu, Jinwei, additional, Leaf, Elizabeth M., additional, Treichel, Catherine, additional, Litvicov, Patrisia, additional, Li, Zhe, additional, Goodson, Alexander D., additional, Rivera-Sánchez, Paula, additional, Bratovianu, Ana-Maria, additional, Baek, Minkyung, additional, King, Neil P., additional, Ruohola-Baker, Hannele, additional, and Baker, David, additional

Published
2023
Full Text
View/download PDF

20. Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies

Author

Edman, Natasha I, primary, Redler, Rachel L, additional, Phal, Ashish, additional, Schlichthaerle, Thomas, additional, Srivatsan, Sanjay R, additional, Etemadi, Ali, additional, An, Seong, additional, Favor, Andrew, additional, Ehnes, Devon, additional, Li, Zhe, additional, Praetorius, Florian, additional, Gordon, Max, additional, Yang, Wei, additional, Coventry, Brian, additional, Hicks, Derrick R, additional, Cao, Longxing, additional, Bethel, Neville, additional, Heine, Piper, additional, Murray, Analisa N, additional, Gerben, Stacey, additional, Carter, Lauren, additional, Miranda, Marcos, additional, Negahdari, Babak, additional, Lee, Sangwon, additional, Trapnell, Cole, additional, Stewart, Lance, additional, Ekiert, Damian C, additional, Schlessinger, Joseph, additional, Shendure, Jay, additional, Bhabha, Gira, additional, Ruohola-Baker, Hannele, additional, and Baker, David, additional

Published
2023
Full Text
View/download PDF

22. Designed endocytosis-inducing proteins degrade targets and amplify signals

Author

Huang, Buwei, Abedi, Mohamad, Ahn, Green, Coventry, Brian, Sappington, Isaac, Tang, Cong, Wang, Rong, Schlichthaerle, Thomas, Zhang, Jason Z., Wang, Yujia, Goreshnik, Inna, Chiu, Ching Wen, Chazin-Gray, Adam, Chan, Sidney, Gerben, Stacey, Murray, Analisa, Wang, Shunzhi, O’Neill, Jason, Yi, Li, Yeh, Ronald, Misquith, Ayesha, Wolf, Anitra, Tomasovic, Luke M., Piraner, Dan I., Duran Gonzalez, Maria J., Bennett, Nathaniel R., Venkatesh, Preetham, Ahlrichs, Maggie, Dobbins, Craig, Yang, Wei, Wang, Xinru, Sahtoe, Danny D., Vafeados, Dionne, Mout, Rubul, Shivaei, Shirin, Cao, Longxing, Carter, Lauren, Stewart, Lance, Spangler, Jamie B., Roybal, Kole T., Greisen, Per Jr, Li, Xiaochun, Bernardes, Gonçalo J. L., Bertozzi, Carolyn R., and Baker, David

Abstract

Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2(LYTACs) and cytokine receptor-targeting chimeras3(KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand–receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody–drug and antibody–RNA conjugates.

Published
2024
Full Text
View/download PDF

23. Accurate de novo design of heterochiral protein–protein interactions

Author

Sun, Ke, Li, Sicong, Zheng, Bowen, Zhu, Yanlei, Wang, Tongyue, Liang, Mingfu, Yao, Yue, Zhang, Kairan, Zhang, Jizhong, Li, Hongyong, Han, Dongyang, Zheng, Jishen, Coventry, Brian, Cao, Longxing, Baker, David, Liu, Lei, and Lu, Peilong

Abstract

Abiotic d-proteins that selectively bind to natural l-proteins have gained significant biotechnological interest. However, the underlying structural principles governing such heterochiral protein–protein interactions remain largely unknown. In this study, we present the de novo design of d-proteins consisting of 50–65 residues, aiming to target specific surface regions of l-proteins or l-peptides. Our designer d-protein binders exhibit nanomolar affinity toward an artificial l-peptide, as well as two naturally occurring proteins of therapeutic significance: the D5 domain of human tropomyosin receptor kinase A (TrkA) and human interleukin-6 (IL-6). Notably, these d-protein binders demonstrate high enantiomeric specificity and target specificity. In cell-based experiments, designer d-protein binders effectively inhibited the downstream signaling of TrkA and IL-6 with high potency. Moreover, these binders exhibited remarkable thermal stability and resistance to protease degradation. Crystal structure of the designed heterochiral d-protein–l-peptide complex, obtained at a resolution of 2.0 Å, closely resembled the design model, indicating that the computational method employed is highly accurate. Furthermore, the crystal structure provides valuable information regarding the interactions between helical l-peptides and d-proteins, particularly elucidating a novel mode of heterochiral helix–helix interactions. Leveraging the design of d-proteins specifically targeting l-peptides or l-proteins opens up avenues for systematic exploration of the mirror-image protein universe, paving the way for a diverse range of applications.

Published
2024
Full Text
View/download PDF

25. Top-down design of protein nanomaterials with reinforcement learning

Author

Lutz, Isaac D., primary, Wang, Shunzhi, additional, Norn, Christoffer, additional, Borst, Andrew J., additional, Zhao, Yan Ting, additional, Dosey, Annie, additional, Cao, Longxing, additional, Li, Zhe, additional, Baek, Minkyung, additional, King, Neil P., additional, Ruohola-Baker, Hannele, additional, and Baker, David, additional

Published
2022
Full Text
View/download PDF

29. Protein-binding proteins designed from target structural information

Author

DeBouver, Nicholas, primary, Cao, Longxing, additional, Coventry, Brian, additional, Bera, Asim, additional, Yang, Wei, additional, Bernard, Steffen, additional, Stewart, Lance, additional, Wilson, Ian, additional, Ruohola-Baker, Hannele, additional, Schlessinger, Joseph, additional, Lee, Sangwon, additional, Savvides, Savvas, additional, and Garcia, K. Christopher, additional

Published
2022
Full Text
View/download PDF

30. Rapid and Sensitive Detection of Antigen from SARS-CoV-2 Variants of Concern by a Multivalent Minibinder-Functionalized Nanomechanical Sensor

Author

Agarwal, Dilip Kumar, primary, Hunt, Andrew C., additional, Shekhawat, Gajendra S., additional, Carter, Lauren, additional, Chan, Sidney, additional, Wu, Kejia, additional, Cao, Longxing, additional, Baker, David, additional, Lorenzo-Redondo, Ramon, additional, Ozer, Egon A., additional, Simons, Lacy M., additional, Hultquist, Judd F., additional, Jewett, Michael C., additional, and Dravid, Vinayak P., additional

Published
2022
Full Text
View/download PDF

32. Large-scale design and refinement of stable proteins using sequence-only models

Author

Singer, Jedediah M., primary, Novotney, Scott, additional, Strickland, Devin, additional, Haddox, Hugh K., additional, Leiby, Nicholas, additional, Rocklin, Gabriel J., additional, Chow, Cameron M., additional, Roy, Anindya, additional, Bera, Asim K., additional, Motta, Francis C., additional, Cao, Longxing, additional, Strauch, Eva-Maria, additional, Chidyausiku, Tamuka M., additional, Ford, Alex, additional, Ho, Ethan, additional, Zaitzeff, Alexander, additional, Mackenzie, Craig O., additional, Eramian, Hamed, additional, DiMaio, Frank, additional, Grigoryan, Gevorg, additional, Vaughn, Matthew, additional, Stewart, Lance J., additional, Baker, David, additional, and Klavins, Eric, additional

Published
2022
Full Text
View/download PDF

34. Robust de novo design of protein binding proteins from target structural information alone

Author

Cao, Longxing, primary, Coventry, Brian, additional, Goreshnik, Inna, additional, Huang, Buwei, additional, Park, Joon Sung, additional, Jude, Kevin M., additional, Marković, Iva, additional, Kadam, Rameshwar U., additional, Verschueren, Koen H.G., additional, Verstraete, Kenneth, additional, Walsh, Scott Thomas Russell, additional, Bennett, Nathaniel, additional, Phal, Ashish, additional, Yang, Aerin, additional, Kozodoy, Lisa, additional, DeWitt, Michelle, additional, Picton, Lora, additional, Miller, Lauren, additional, Strauch, Eva-Maria, additional, Halabiya, Samer, additional, Hammerson, Bradley, additional, Yang, Wei, additional, Benard, Steffen, additional, Stewart, Lance, additional, Wilson, Ian A., additional, Ruohola-Baker, Hannele, additional, Schlessinger, Joseph, additional, Lee, Sangwon, additional, Savvides, Savvas N., additional, Garcia, K. Christopher, additional, and Baker, David, additional

Published
2021
Full Text
View/download PDF

36. Multivalent designed proteins protect against SARS-CoV-2 variants of concern

Author

Hunt, Andrew C., primary, Case, James Brett, additional, Park, Young-Jun, additional, Cao, Longxing, additional, Wu, Kejia, additional, Walls, Alexandra C., additional, Liu, Zhuoming, additional, Bowen, John E., additional, Yeh, Hsien-Wei, additional, Saini, Shally, additional, Helms, Louisa, additional, Zhao, Yan Ting, additional, Hsiang, Tien-Ying, additional, Starr, Tyler N., additional, Goreshnik, Inna, additional, Kozodoy, Lisa, additional, Carter, Lauren, additional, Ravichandran, Rashmi, additional, Green, Lydia B., additional, Matochko, Wadim L., additional, Thomson, Christy A., additional, Vögeli, Bastain, additional, Krüger-Gericke, Antje, additional, VanBlargan, Laura A., additional, Chen, Rita E., additional, Ying, Baoling, additional, Bailey, Adam L., additional, Kafai, Natasha M., additional, Boyken, Scott, additional, Ljubetič, Ajasja, additional, Edman, Natasha, additional, Ueda, George, additional, Chow, Cameron, additional, Addetia, Amin, additional, Panpradist, Nuttada, additional, Gale, Michael, additional, Freedman, Benjamin S., additional, Lutz, Barry R., additional, Bloom, Jesse D., additional, Ruohola-Baker, Hannele, additional, Whelan, Sean P. J., additional, Stewart, Lance, additional, Diamond, Michael S., additional, Veesler, David, additional, Jewett, Michael C., additional, and Baker, David, additional

Published
2021
Full Text
View/download PDF

37. Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease

Author

Case, James Brett, primary, Chen, Rita E., additional, Cao, Longxing, additional, Ying, Baoling, additional, Winkler, Emma S., additional, Johnson, Max, additional, Goreshnik, Inna, additional, Pham, Minh N., additional, Shrihari, Swathi, additional, Kafai, Natasha M., additional, Bailey, Adam L., additional, Xie, Xuping, additional, Shi, Pei-Yong, additional, Ravichandran, Rashmi, additional, Carter, Lauren, additional, Stewart, Lance, additional, Baker, David, additional, and Diamond, Michael S., additional

Published
2021
Full Text
View/download PDF

38. Large-scale design and refinement of stable proteins using sequence-only models

Author

Singer, Jedediah M., primary, Novotney, Scott, additional, Strickland, Devin, additional, Haddox, Hugh K., additional, Leiby, Nicholas, additional, Rocklin, Gabriel J., additional, Chow, Cameron M., additional, Roy, Anindya, additional, Bera, Asim K., additional, Motta, Francis C., additional, Cao, Longxing, additional, Strauch, Eva-Maria, additional, Chidyausiku, Tamuka M., additional, Ford, Alex, additional, Ho, Ethan, additional, Mackenzie, Craig O., additional, Eramian, Hamed, additional, DiMaio, Frank, additional, Grigoryan, Gevorg, additional, Vaughn, Matthew, additional, Stewart, Lance J., additional, Baker, David, additional, and Klavins, Eric, additional

Published
2021
Full Text
View/download PDF

39. Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice

Author

Case, James Brett, primary, Chen, Rita E., additional, Cao, Longxing, additional, Ying, Baoling, additional, Winkler, Emma S., additional, Goreshnik, Inna, additional, Shrihari, Swathi, additional, Kafai, Natasha M., additional, Bailey, Adam L., additional, Xie, Xuping, additional, Shi, Pei-Yong, additional, Ravichandran, Rashmi, additional, Carter, Lauren, additional, Stewart, Lance, additional, Baker, David, additional, and Diamond, Michael S., additional

Published
2021
Full Text
View/download PDF

40. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Author

Cao, Longxing, primary, Goreshnik, Inna, additional, Coventry, Brian, additional, Case, James Brett, additional, Miller, Lauren, additional, Kozodoy, Lisa, additional, Chen, Rita E., additional, Carter, Lauren, additional, Walls, Alexandra C., additional, Park, Young-Jun, additional, Strauch, Eva-Maria, additional, Stewart, Lance, additional, Diamond, Michael S., additional, Veesler, David, additional, and Baker, David, additional

Published
2020
Full Text
View/download PDF

41. De novo design of modular and tunable allosteric biosensors

Author

Quijano-Rubio, Alfredo, primary, Yeh, Hsien-Wei, additional, Park, Jooyoung, additional, Lee, Hansol, additional, Langan, Robert A., additional, Boyken, Scott E., additional, Lajoie, Marc J., additional, Cao, Longxing, additional, Chow, Cameron M., additional, Miranda, Marcos C., additional, Wi, Jimin, additional, Hong, Hyo Jeong, additional, Stewart, Lance, additional, Oh, Byung-Ha, additional, and Baker, David, additional

Published
2020
Full Text
View/download PDF

45. Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome

Author

Savira, Feby, primary, Cao, Longxing, additional, Wang, Ian, additional, Yang, Wendi, additional, Huang, Kevin, additional, Hua, Yue, additional, Jucker, Beat M., additional, Willette, Robert N., additional, Huang, Li, additional, Krum, Henry, additional, Li, Zhiliang, additional, Fu, Qiang, additional, and Wang, Bing Hui, additional

Published
2017
Full Text
View/download PDF

48. Renal denervation: a new therapeutic approach for resistant hypertension

Author

Cao Longxing, Fu Qiang, Wang Binghui, and Li Zhiliang

Subjects
Sympathetic Nervous System, Hypertension, Humans, Blood Pressure, General Medicine, Kidney, Denervation, Neurosurgical Procedures
Abstract

To review the advances in studies on renal denervation.References concerning renal denervation and resistant hypertension cited in this review were collected from PubMed published in English and those of renal denervation devices from official websites of device manufacturers up to January 2014.Articles with keywords "renal denervation" and "resistant hypertension" were selected.Renal and systemic sympathetic overactivity plays an important role in pathology of hypertension as well as other diseases characterized by sympathetic overactivity. Renal denervation is a new, catheter based procedure to reduce renal and systemic sympathetic overactivity by disruption of renal sympathetic efferent and afferent nerves through radiofrequency or ultrasound energy delivered to the endoluminal surface of both renal arteries. Although several studies have shown the efficacy and safety of renal denervation in the treatment of resistant hypertension and the potential benefit of the procedure in other diseases, Symplicity HTN 3 study, the most rigorous clinical trial of renal denervation to date, failed to meet its primary endpoint. The procedure also has other limitations such as the lack of long term, efficacy and safety data and the lack of the predictors for the blood pressure lowering response and nonresponse to the procedure. An overview of current renal denervation devices holding Conformité Européenne mark is also included in this review.Renal denervation is a promising therapeutic approach in the management of resistant hypertension and other diseases characterized by sympathetic overactivity. In its early stage of clinical application, the efficacy of the procedure is still controversial. Large scale, blind, randomized, controlled clinical trials are still necessary to address the limitations of the procedure.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results